Comparative Pharmacology
Head-to-head clinical analysis: KOVANAZE versus PROMETHAZINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KOVANAZE versus PROMETHAZINE.
KOVANAZE vs PROMETHAZINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
KOVANAZE (norepinephrine and phenylephrine) is a combination of two vasopressors: norepinephrine, an α1-adrenergic receptor agonist with β1-adrenergic activity, and phenylephrine, a selective α1-adrenergic receptor agonist. Both agents cause vasoconstriction and increase blood pressure via activation of α1-adrenergic receptors on vascular smooth muscle.
Promethazine is a phenothiazine derivative that acts as a potent histamine H1 receptor antagonist, thereby blocking the effects of histamine. It also has central anticholinergic, antiemetic, and sedative properties, likely mediated through antagonism at muscarinic, dopamine D2, and serotonin receptors in the brain.
Intravenous bolus of 1 mg/kg over 10 minutes, followed by intravenous infusion of 0.02 mg/kg/min for 4 hours, then 0.01 mg/kg/min for 20 hours.
12.5-25 mg IM or IV every 4-6 hours; also 25 mg PO or PR every 6-8 hours. Maximum 100 mg/day.
None Documented
None Documented
Clinical Note
moderatePromethazine + Risedronic acid
"Promethazine can cause an increase in the absorption of Risedronic acid resulting in an increased serum concentration and potentially a worsening of adverse effects."
Clinical Note
moderatePromethazine + Methylphenidate
"Promethazine can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects."
Clinical Note
moderatePromethazine + Artesunate
"The serum concentration of Artesunate can be increased when it is combined with Promethazine."
Clinical Note
moderateTerminal elimination half-life: approximately 7-9 hours following nasal administration; clinical significance: supports twice-daily dosing regimen
Terminal elimination half-life 9-16 hours; may be prolonged in hepatic impairment.
Renal excretion of unchanged drug: ~20-30%; fecal/biliary elimination: minimal (<5%); remainder as metabolites
Renal (70-80% as metabolites, <1% unchanged); biliary/fecal minor.
Category C
Category A/B
Antihistamine + Corticosteroid Combination
Antihistamine / Antiemetic
Promethazine + Clotrimazole
"The metabolism of Clotrimazole can be decreased when combined with Promethazine."